← Back to Search

CAR T-cell Therapy

Long-Term Follow-Up of P-BCMA-101 for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Poseida Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up rimiducid infusion through year 15 after p-bcma-101 infusion, if applicable
Awards & highlights
No Placebo-Only Group

Summary

This trial will follow subjects for 15 years to assess long-term safety and effectiveness of P-BCMA-101 T cells. Rimiducid may be given as needed.

Who is the study for?
This trial is for individuals who have previously received P-BCMA-101 T cell treatment for multiple myeloma, either completing or discontinuing early from a Poseida sponsored study. Participants must consent to long-term follow-up.
What is being tested?
The study monitors the safety and effectiveness of P-BCMA-101 T cells over 15 years post-treatment. It evaluates the risk of delayed side effects, ongoing benefits, and tracks levels of these specialized T cells in subjects.
What are the potential side effects?
While specific side effects are not listed, this trial will assess any delayed adverse events related to P-BCMA-101 T cell therapy that may occur over the long term.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~rimiducid infusion through year 15 after p-bcma-101 infusion, if applicable
This trial's timeline: 3 weeks for screening, Varies for treatment, and rimiducid infusion through year 15 after p-bcma-101 infusion, if applicable for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Secondary study objectives
Anti-myeloma effect of P-BCMA-101 (Duration of Response)
Anti-myeloma effect of P-BCMA-101 (Overall Survival)
Anti-myeloma effect of P-BCMA-101 (Progression Free Survival)
+8 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: P-BCMA-101 treatedExperimental Treatment1 Intervention
Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.

Find a Location

Who is running the clinical trial?

Poseida Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
696 Total Patients Enrolled
2 Trials studying Multiple Myeloma
336 Patients Enrolled for Multiple Myeloma
California Institute for Regenerative Medicine (CIRM)OTHER
69 Previous Clinical Trials
3,258 Total Patients Enrolled
1 Trials studying Multiple Myeloma
105 Patients Enrolled for Multiple Myeloma
Rajesh Belani, M.D.Study DirectorSponsor Executive Medical Director
4 Previous Clinical Trials
576 Total Patients Enrolled
2 Trials studying Multiple Myeloma
336 Patients Enrolled for Multiple Myeloma

Media Library

P-BCMA-101 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03741127 — Phase 1
Multiple Myeloma Research Study Groups: P-BCMA-101 treated
Multiple Myeloma Clinical Trial 2023: P-BCMA-101 Highlights & Side Effects. Trial Name: NCT03741127 — Phase 1
P-BCMA-101 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03741127 — Phase 1
~56 spots leftby Aug 2032
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top